Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma.

Shinpei YamabaYukinori ImaiKayoko SugawaraYoshihito UchidaAkira FuchigamiHiroshi UchiyaNobuaki NakayamaSatoshi Mochida

Published in: PloS one (2024)

ATZ/BEV merits consideration even for MTA-experienced patients, since the OS was equivalent to those in MTA-naïve patients despite of an unfavorable early therapeutic efficacy.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
squamous cell carcinoma
patient reported outcomes